Skip to main content

Month: April 2024

DSV, 1103 – INTERIM FINANCIAL REPORT Q1 2024

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Company Announcement No. 1103 Selected key figures and ratios for the period 1 January – 31 March 2024  Q1 2024 Q1 2023Key figures (DKKm)    Revenue 38,340 40,954Gross profit 10,265 11,391Operating profit (EBIT) before special items 3,641 4,672Profit for the period 2,393 3,287Adjusted earnings for the period 2,463 3,340     Ratios    Conversion ratio 35.5% 41.0%Diluted adjusted earnings per share of DKK 1 for the last 12 months 55.3 76.9Jens H. Lund, Group CEO: “In a normalising market, we are off to a good start delivering strong financial results in the first quarter of 2024, and I am particularly satisfied that we are gaining market shares in all three divisions. We have also completed the leadership changes, the organisation has settled, and together with the new and experienced leadership team we...

Continue reading

Ringkjøbing Landbobank’s quarterly report for the first quarter of 2024

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Nasdaq CopenhagenLondon Stock ExchangeEuronext DublinOther stakeholders 24 April 2024Ringkjøbing Landbobank’s quarterly report for the first quarter of 2024 The bank’s board of directors and general management today approved the quarterly report for the first quarter of 2024. The bank delivers core earnings of DKK 793 million and net profit of DKK 616 million in the first quarter of the year. The net profit is equivalent to a 24% p.a. return on equity.Core earnings(DKK million) Q1 2024 Q1 2023 2023 2022 2021 2020Total core income 1,040 849 3,828 2,862 2,433 2,179Total expenses and depreciation 247 227 963 891 817 788Core earnings before impairment charges for loans 793 622 2,865 1,971 1,616 1,391Impairment charges for loans etc. 0 -1 -1 -2 -68 -223Core earnings 793 621 2,864 1,969 1,548 1,168Result for the portfolio...

Continue reading

Q1 2024 results: KPN delivers solid start to the year

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Continued Group service revenue growth (+3.6% y-on-y), mainly driven by Consumer (+4.5%) and Business (+3.2%) Ongoing positive net adds in Consumer postpaid +30k and broadband +13k, of which 8k related to Kabeltex acquisition Expanded fiber footprint with +130k HP in Q1 2024 (+159k HP including Glaspoort) Adj. EBITDA AL of € 605m (+3.6% y-on-y), quarterly FCF generation impacted by intra-year phasing ACM unconditionally approved Youfone acquisition, transaction closed on 4 April Full year 2024 outlook raised to ~€ 2,500m adjusted EBITDA AL and >€ 890m FCF, reflecting Youfone acquisition On track to reach mid-term ambitions; including cumulative shareholder distributionsProgram 12:45 CEST: Registration of attendees13:00 CEST: Webcast The webcast and documents can be accessed via our website ir.kpn.com Formal disclosures Royal KPN N.V....

Continue reading

EXEL Industries : Second quarter 2023–2024 sales: up 1.8%

Written by Customer Service on . Posted in Public Companies.

Second quarter 2023-2024 sales: down 1.8% Varying sales performance across activitiesQ2 sales(January 2024–March 2024)   2022-2023 2023-2024 Change (reported) Change (LFL*)Reported Reported €m % €m %             AGRICULTURAL SPRAYING   147.7 157.4 +9.7 +6.5% +12.0 +8.1%SUGAR BEET HARVESTERS   34.3 17.1 -17.2 -50.1% -17.1 -49.9%LEISURE     48.4 47.4 -1.0 -2.0% -4.4 -9.0%INDUSTRY     67.6 70.7 +3.1 +4.7% +3.3 +4.9%             EXEL Industries Group 297.9 292.6 -5.3 -1.8% -6.2 -2.1%6-monthsales(October 2023–March 2024)   2022-2023 2023-2024 Change (reported) Change (LFL*)Reported Reported €m % €m %             AGRICULTURAL...

Continue reading

Vistin Pharma ASA: First quarter 2024 financial results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Oslo, Norway, 24th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales volume in the quarter was up by 11% compared to Q1 2023. First quarter EBITDA ended at MNOK 20 compared to MNOK 14 in Q1 2023, representing a 45% increase. EBITDA positively affected by increased sales volume and product mix, partly offset by a one-time inventory adjustment of MNOK 7. The net profit ended at MNOK 7.7 for the first quarter of 2024. Net profit negatively affected with approx. MNOK 3 in the quarter by fair value of future FX cash flow hedging contracts (unrealized gain – no cash effect in quarter). Unplanned “wear and tear” maintenance/repair on Line 2 resulted in lower than planned production and sales volume...

Continue reading

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Written by Customer Service on . Posted in Public Companies.

Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare Impact Awards honor individuals, groups and organizations who are making exceptional strides to improve the lives of people living with rare diseases. Pharming will accept the award in recognition of the U.S. Food and Drug Administration (FDA) approval and commercialization of Joenja® (leniolisib), an oral, selective PI3Kδ inhibitor. Joenja® is the first and only...

Continue reading

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Written by Customer Service on . Posted in Public Companies.

PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.       Q1 2024   Q1 2023   % change  €m   €m   Actual CER1Growth platforms2 509.7 452.0 12.8% 16.2%New medicines3 45.5 14.3 n/a n/aSomatuline® 257.8 263.2 -2.0% -1.3%Other 9.5 12.4 -23.8% -20.5%Total Sales 822.4 741.9 10.9% 13.3%HighlightsTotal-sales growth of 13.3% at CER1, or 10.9% as reported, driven by the 16.2%1 increase in sales of the growth platforms2 and the increased contributions from new medicines, while Somatuline sales declined by only 1.3%1Regulatory approval and launch of Onivyde in the U.S. as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) Confirmation of financial guidance for 2024...

Continue reading

TGS Q1 2024 Presentation and Webcast

Written by Customer Service on . Posted in Public Companies.

OSLO, Norway (24 April 2024) – TGS will release its Q1 2024 results at approximately 07:00 CEST on 8 May 2024. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at House of Oslo, Ruseløkkveien 34, Oslo, Norway. The presentation is open to the public and can be followed live online. Access and registration for online attendees are available by copying and pasting this link into your browser: https://channel.royalcast.com/landingpage/hegnarmedia/20240508_16/ The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. For more information, visit TGS.com (http://www.tgs.com) or contact: CFO Sven Børre LarsenE-mail: investor@tgs.com Company SummaryTGS provides scientific data and intelligence to companies active in the energy sector. In addition...

Continue reading

BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023

Written by Customer Service on . Posted in Public Companies.

PRESS RELEASE – PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis. Mont-Saint-Guibert, Belgium, 24 April 2024, 7:00 am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases, today announces the postponing of the publication of its 2023 annual report, as well as the annual general meeting of its shareholders, so that the Enterprise Court...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.